
-
2014
Company Description
Delivering cures for neurodegenerative diseases.
Lysosomal Therapeutics Inc. (LTI) is dedicated to innovative small-molecule research and development in the field of neurodegeneration, yielding new treatment options for patients with severe neurological diseases. Our strategy leverages the clinically-validated link between lysosome-based genetic disorders and neurodegenerative diseases to establish a unique and effective molecular platform for novel drug discovery. LTI’s lead program targets Gaucher-related neurodegeneration, Parkinson’s disease and other synucleinopathies.
-
Manufacturer:
Science and Engineering -
Formed:
2014 -
Founders:
Peter Wirth -
Company Website:
-
Company E-mail:
-
Company Address:
19 Blackstone StreetCambridge, MAUnited States -
CEO:
- Peter Wirth
-
We recognize our sponsors starting at $1 per entry.
Learn more at https://www.ithistory.org/benefits